Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study.
Van Laethem JL, Borbath I, Prenen H, Geboes KP, Lambert A, Mitry E, Cassier PA, Blanc JF, Pilla L, Batlle JF, Garrote MR, Pazo-Cid RA, Gallego I, Smith KE, Ellmark P, Pico de Coaña Y, Ambarkhane SV, Macarulla T.
Van Laethem JL, et al.
Lancet Oncol. 2024 May 31:S1470-2045(24)00263-8. doi: 10.1016/S1470-2045(24)00263-8. Online ahead of print.
Lancet Oncol. 2024.
PMID: 38834087